Skip to main content
TipRanks
Go Ultimate75% OFF

Amrutanjan Health Care Limited (AMRUTANJAN) AI Stock Analysis

1 Followers
IN:AMRUTANJAN

Amrutanjan Health Care Limited

(NSE:AMRUTANJAN)

Select Model
Rating:62Neutral
Price Target:INR 537.00â–²(5.10% Upside)
Action:reiterated
Date:11/18/26

The score is driven primarily by solid financial resilience and a very conservative balance sheet, offset by weak recent cash-flow conversion and negative free cash flow in 2026. Technicals are neutral-to-slightly positive short term but weaker over the longer trend, while valuation appears only moderately attractive with a low dividend yield.

Positive Factors
Very Low LeverageExtremely low leverage reduces financial risk and limits interest-related pressure on earnings and cash flow. It also gives Amrutanjan greater flexibility to fund products, marketing, or expansion internally and provides resilience if operating conditions weaken over the next several quarters.
Negative Factors
Weak Cash-Flow ConversionWeak conversion of accounting profit into operating cash reduces the quality and flexibility of earnings. Negative free cash flow in 2026 may constrain reinvestment, dividends, or other capital allocation choices unless cash generation improves, even though the balance sheet remains conservatively funded.

Amrutanjan Health Care Limited (AMRUTANJAN) vs. iShares MSCI India ETF (INDA)

-30%-25%-20%-15%-10%-5%0%5%IN:AMRUTANJAN-24.43%INDA-2.43%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 14.82B
Dividend Yield
0.96%
Average Volume (3M)
1,917
Price to Earnings (P/E)
25.9
Beta (1Y)
0.76
Revenue Growth
12.56%
EPS Growth
1.03%
Country
India
Employees
634
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Amrutanjan Health Care Limited Business Overview & Revenue Model

Company Description

Established in Chennai, India, in 1893, Amrutanjan Health Care Limited, formerly known as Amrutanjan Limited until its renaming in 2007, is a prominent manufacturer, supplier, and vendor of a broad array of wellness products. The company primarily op...

Amrutanjan Health Care Limited Financial Statement Overview

Summary

Profitability is steady with net margins around ~10.5%–11.5% (2023–2026) and revenue growth remains positive, but growth slowed in 2026 and margins have compressed versus 2021–2022. The balance sheet is a major strength with extremely low leverage, but cash-flow quality is a key concern given weak cash conversion and negative free cash flow in 2026.

Income Statement

64Positive

Balance Sheet

90Very Positive

Cash Flow

40Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue5.29B5.03B4.51B4.21B3.80B4.05B
Gross Profit2.42B1.88B2.46B1.46B1.98B2.25B
EBITDA806.17M756.85M758.79M681.60M590.79M946.99M
Net Income572.91M579.18M508.35M449.73M398.35M671.89M
Balance Sheet
Total Assets5.15B5.09B4.21B3.67B3.62B3.50B
Cash, Cash Equivalents and Short-Term Investments1.85B363.99M1.95B2.07B1.93B2.01B
Total Debt18.90M17.77M20.78M17.28M9.09M8.80M
Total Liabilities1.31B1.39B947.73M783.82M713.21M847.44M
Stockholders Equity3.84B3.70B3.27B2.88B2.91B2.65B
Cash Flow
Free Cash Flow0-31.16M153.46M211.93M102.91M287.32M
Operating Cash Flow0518.88M508.99M279.11M192.18M521.96M
Investing Cash Flow0-371.49M-309.66M191.65M-24.75M-362.12M
Financing Cash Flow0-136.22M-134.90M-482.66M-140.26M-167.02M

Amrutanjan Health Care Limited Technical Analysis

Technical Analysis SentimentNeutral
Last Price510.95

Price Trends

50DMA503.26Positive
100DMA510.31Positive
200DMA534.04Negative

Market Momentum

MACD3.06Negative
RSI53.51Neutral
STOCH42.45Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:AMRUTANJAN, the sentiment is Neutral. The current price of 510.95 is above the 20-day moving average (MA) of 504.52, above the 50-day MA of 503.26, and below the 200-day MA of 534.04, indicating a neutral trend. The MACD of 3.06 indicates Negative momentum. The RSI at 53.51 is Neutral, neither overbought nor oversold. The STOCH value of 42.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:AMRUTANJAN.

Amrutanjan Health Care Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

IN:AMRUTANJAN against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:VENUSREMIN:VENUSREM72OutperformINR 19.89B16.38―0.67%20.22%73.03%
IN:MANKINDIN:MANKIND67NeutralINR 1.10T49.05―0.04%13.27%27.32%
IN:PGHLIN:PGHL64NeutralINR 93.00B24.43―3.77%16.05%23.81%
IN:AMRUTANJANIN:AMRUTANJAN62NeutralINR 14.94B25.86―0.96%12.56%1.03%
IN:BLISSGVSIN:BLISSGVS61NeutralINR 68.38B42.36―0.23%24.87%46.37%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
IN:INDOCOIN:INDOCO43NeutralINR 21.40B68.28―0.09%10.75%―

* Healthcare Sector Average

Performance Comparison

0%100%200%300%IN:AMRUTANJANIN:BLISSGVSIN:INDOCOIN:MANKINDIN:PGHLIN:VENUSREMDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:AMRUTANJAN and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:AMRUTANJANAmrutanjan Health Care Limited510.95-172.04-25.19%
IN:BLISSGVSBliss Gvs Pharma Limited643.10474.25280.87%
IN:INDOCOIndoco Remedies Limited231.80-21.18-8.37%
IN:MANKINDMankind Pharma Ltd.2660.00440.0019.82%
IN:PGHLProcter & Gamble Health Ltd.5602.70-58.88-1.04%
IN:VENUSREMVenus Remedies Limited1488.10775.89108.94%

Amrutanjan Health Care Limited Corporate Events

Amrutanjan Health Care Releases September 2026 Investor Presentation

Nov 3, 2026

The company submitted its investor presentation for the quarter and half year ended September 30, 2026, under applicable securities-disclosure requirements. The release signals a focus on execution and stronger momentum, while providing investors wit...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 17, 2026